We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Facing claims it induced doctors to prescribe a generic version of GlaxoSmithKline’s Coreg that violated its patents, Teva was hit with a hefty $235 million penalty in 2017. But a federal judge overruled that jury’s verdict last year—and now, one federal